Wednesday, July 8, 2026

Patent intelligence · US

US 12377102

Compounds for the prevention and treatment of medical disorders and uses thereof

granted A61KA61K31/519A61K45/06A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 20
Patent details — US 12377102
Jurisdiction
US
Status
granted
Grant date
Aug 5, 2025
Expiration
Jul 31, 2045
Claims
3
CPC classes
A61K, A61K31/519, A61K45/06, A61P
View on Google Patents ↗

Quick answer

US 12377102 (Compounds for the prevention and treatment of medical disorders and uses thereof) is held by Galectin Sciences, LLC. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
3
CPC classes
A61K, A61K31/519, A61K45/06, A61P, A61P1/16, A61P11/06

More from Galectin Sciences, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 11583530

    Compounds for the prevention and treatment of medical disorders and uses thereof

    Galectin Sciences, LLC · Expires Feb 16, 2043

    granted
  2. US 11576924

    Compounds for the prevention and treatment of diseases and the use thereof

    Galectin Sciences, LLC · Expires Feb 9, 2043

    granted
  3. US 11413303

    Methods for treatment of arthritis

    GALECTIN THERAPEUTICS, INC. · Expires Aug 11, 2042

    granted
  4. US 10799525

    Composition of novel carbohydrate drug for treatment of human diseases

    GALECTIN THERAPEUTICS, INC. · Expires Oct 8, 2040

    granted
  5. US 10744154

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    GALECTIN THERAPEUTICS, INC. · Expires Aug 13, 2040

    granted
  6. US 10420793

    Composition of novel carbohydrate drug for treatment of human diseases

    GALECTIN THERAPEUTICS, INC. · Expires Sep 19, 2039

    granted
  7. US 9974802

    Composition of novel carbohydrate drug for treatment of human diseases

    GALECTIN THERAPEUTICS, INC. · Expires May 17, 2038

    granted

Frequently asked questions

What is US patent 12377102?

US 12377102 (Compounds for the prevention and treatment of medical disorders and uses thereof) is held by Galectin Sciences, LLC. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12377102?

Galectin Sciences, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.

When does US 12377102 expire?

Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.